BRCA2 and ovarian carcinoma: The copy number gain of EMSY, which binds to BRCA2, exon 3, has been described in 17% of high-grade ovarian cancer, and it has been reported as an alternative mechanism for HRD, even if its role is controversial and it does not seem to confer sensitivity to PARPis [32,33,34].